Skip to content

Nuvectis Pharma, Inc. NVCT Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$65.65K+260%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
$334K+5,467%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$578K
Nektar Therapeutics logo
Nektar TherapeuticsNKTR

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Nuvectis Pharma, Inc.’s 10-K, filed February 25, 2025, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s payments of stock issuance costs?
Nuvectis Pharma, Inc. (NVCT) reported payments of stock issuance costs of $124K in Q4 2024.